• Profile
Close

Interleukin-27 is a potential marker for the onset of post-transplant malignancies

Nephrology Dialysis Transplantation Jan 10, 2019

Pontrelli P, et al. - Researchers performed this multicentre, observational, perspective, case–control study to determine a soluble diagnostic marker for monitoring the development of post-transplant malignancies. This study included 47 patients with post-transplant solid neoplasia and 106 transplant recipients without a history of neoplasia as controls. Comparing patients with and without post-transplant malignancies, 535 differentially expressed genes were identified. A close association of the cancer pathway with gene expression data was noted, and interleukin-27 (IL-27), a cytokine regulating anti-tumour immunity, was identified as one of the most down-regulated genes in this pathway. The microarray data were corroborated using quantitative polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA). With a specificity of 80% and a sensitivity of 81%, IL-27 plasma levels allowed differentiation of patients with post-transplant neoplasia. Using an independent set of patients from two different transplant centres, this finding was corroborated. Overall, IL-27 could have the potential as an immunological marker to offer timely detection of post-transplant neoplasia.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay